This resource has been developed to provide you with important information about Acute Lymphoblastic Leukemia (ALL) as well as Oncaspar® as a treatment option.

Sustained Asparagine depletion starts with Oncaspar®.
Sustained Activity. Proven Results.

Oncaspar News

Makers of Oncaspar® (pegaspargase) announce new pricing for medicine after $50 million effort to avert drug shortage. Click here for more information.

Every hero needs a cape—get one for your superhero with a customized Comfort Cape from Sigma-Tau Pharmaceuticals and Wonder Capes. Learn more now!

S.O.S.   Sigma-Tau Outreach Services

Benefits verification, Co-Pay assistance,
Patient Assistance Program,
Reimbursement Specialists.
For more details on this resource, click here.

Call 1-800-490-3262


Oncaspar® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the first line treatment of patients with acute lymphoblastic leukemia (ALL) and for the treatment of patients with ALL and hypersensitivity to native forms of L-asparaginase.

Important Safety Information

Oncaspar® is contraindicated in patients with a history of serious allergic reactions to Oncaspar®, and in patients with a history of serious thrombosis, pancreatitis, or serious hemorrhagic events with prior L-asparaginase therapy.

Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue Oncaspar in patients with serious allergic reactions.

Patients with abdominal pain should be evaluated for evidence of pancreatitis. Discontinue Oncaspar in patients with pancreatitis. Oncaspar should also be discontinued in patients with serious thrombotic events.

Glucose intolerance, in some cases irreversible, can occur; serum glucose should be monitored. Coagulopathy and hepatotoxicity can occur; appropriate monitoring should be performed.

The most common adverse reactions with Oncaspar® (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.

Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to Oncaspar. Please click here to review full Product Information.